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Betatrophin is a protein which is produced by the liver and by
adipose tissue. There are no clear data about serum betatrophin's
cardiovascular role and it is unknown, whether betatrophin is
associated with the risk of cardiovascular death. This article pro-
vides additional data on the association of betatrophin with its
power to predict cardiovascular death in coronary patients. In
addition, this data article demonstrates the performance of beta-
trophin as a biomarker using c-statistics. Analyzed data was
derived from 553 coronary patients. Betatrophin was measured in
serum samples and cardiovascular deaths were recorded for a
median of 7.1 years. This data article is related to a research article
titled “High betatrophin in coronary patients protects from car-
diovascular events” [1].
© 2019 The Author(s). Published by Elsevier Inc. This is an open
access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).j.atherosclerosis.2019.11.011.
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Specifications table
Subject area Medicine, Clinical Research
More specific subject area Cardiology, Epidemiology, Biomarkers
Type of data Figures, table
How data was acquired ELISA
Data format Raw data and analyzed data
Experimental factors Betatrophin concentration of 553 coronary patients has been determined and
cardiovascular deaths have been recorded for a median of 7.1 years
Experimental features Betatrophin in serum samples was measured by ELISA
Data source location Feldkirch, Austria
Data accessibility Analyzed data is with this article. Raw data is available upon request and approval
(Contact:vivit@lkhf.at).
Related research article Leiherer, A., Ebner, J., Muendlein, A, Brandtner, E., Zach, C. Geiger, K., Fraunberger, P., and
Drexel, H., 2019. High betatrophin in coronary patients protects from cardiovascular events.
Atherosclerosis.
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- No prospective data on the power of betatrophin to predict the cardiovascular risk were available at present.
- Whereas the main article “High betatrophin in coronary patients protects from cardiovascular events” has evaluated the
performance of uromodulin as a biomarker to predict cardiovascular events, this data article is focused on cardiovascular
mortality.
- This data article helps researchers to evaluate the potential of betatrophin as a cardiovascular biomarker over and above
the main article.
- These data are important, because the role of betatrophin in cardiovascular disease is still elusive, and may stimulate
future research on betatrophin.1. Data
It has been mentioned in the main article [1] that there is a significant association between high
betatrophin in serum of 553 coronary patients and a low risk for cardiovascular events. Here, further
data on the association between betatrophin and cardiovascular death are provided. In total 64 pa-
tients succumbed to cardiovascular death. Table 1 gives an overview about the frequency of different
types of cardiovascular deaths. There were no significant differences between different groups
(p ¼ 0.768) nor between vascular-related (vascular death þ fatal insult) and cardiac-related (fatal
myocardial infarction, sudden cardiac death, terminal heart failure, and other cardiac death) deaths
(p¼ 0.692). Fig.1 demonstrates that high betatrophin protects from cardiovascular death during follow
up time. The data summarized in Table 2 shows the comparison of different prediction models for
cardiovascular death. The prediction of cardiovascular deaths is significantly higher applying an
enhanced prediction model comprising betatrophin compared to a basic model lacking betatrophin.
2. Experimental design, materials and methods
2.1. Design and analyses
Characterization and basic laboratory measurement of patients was done as described in the main
article [1]. In short, all 553 coronary patients were recruited between 2005 and 2008. Only patients
who were referred to elective coronary angiography for the evaluation of established or suspected
stable CAD were enrolled. Patients undergoing coronary angiography for other reasons and patients
with acute coronary syndromes were excluded. Serum betatrophin levels were determined with a
commercial uromodulin enzyme-linked immunosorbent assay (ELISA) kit (BioVendor, Brno, Czech
Republic; catalog no. RD191347200R), which was specific for human betatrophin. The inter- and intra-
assay coefficient of variationwas3.9% and 7.4% respectively. Serum betatrophinwas 10.4± 12.9 ng/ml
Table 1
Causes of cardiovascular deaths.
Cause n Betatrophin, mean ± SD (ng/ml)
Vascular death 5 8.2 ± 2.9
Fatal insult 8 6.8 ± 1.9
Fatal myocardial infarction 5 6.6 ± 1.5
Sudden cardiac death 3 4.9 ± 0.9
Terminal heart failure 21 8.4 ± 7.2
Other/unknown cardiac death 22 15.7 ± 28.8
total 64 10.4 ± 17.6
Sixty-four cardiovascular deaths were recorded during follow up. Betatrophin concentration is given as mean ± standard
deviation (SD).
Fig. 1. Betatrophin as predictor of cardiovascular death. The Forest plot represents the hazard ratios (HR) with 95% confidence
interval (CI) for the association between high betatrophin (status) in serum and cardiovascular death risk in the study population.
Model 1 represents a univariate analysis. Model 2 includes the covariates age, gender, and body mass index (BMI). Model 3 includes
the parameters included in model 2 and in addition the concentration of triglycerides, of high density lipoprotein (HDL) and low
density lipoprotein (LDL) cholesterol, and the type 2 diabetes (T2DM), hypertension, current smoking and significant coronary artery
disease (CAD) status. Model 4 includes the parameters included in model 3 and in addition the Vitamin D concentration. Model 5
includes the parameters included in model 4 and in addition the estimated glomerular filtration rate (eGFR) and the concentration of
brain natriuretic peptide (BNP), C-reactive protein (CRP), and troponin I. Model 6 includes the parameters included in model 5 and in
addition the treatment status with respect to acetylsalicylic acid (ASA), beta blocker, angiotensin converting enzyme (ACE) in-
hibitors, angiotensin (AT)-2 receptor antagonists, and statins.
A. Leiherer et al. / Data in brief 28 (2020) 104989 3(mean ± SD) on average and its median was 7.5 ng/ml with an IQR of 5.4e10.6 ng/ml and minimum
(min) and maximum (max) of 1.2 ng/ml and 136.4 ng/ml respectively.
The median follow up time of the study, described in the main article, was 7.1 years with an
interquartile range (IQR) of 5.9e7.5 years. No patients were lost during follow up, resulting in a 100%
follow-up rate. The endpoint “cardiovascular death” was a composite of fatal insult, vascular death,
fatal myocardial infarction, sudden cardiac death, terminal heart failure, and other cardiac death.
2.2. Statistical analysis
Statistical analyses are described in detail in the main article [1]. In particular, to determine the
incidence of the respective endpoint, we used Cox proportional hazards models. In the case continuous
data showed a skewed distribution (skewness >1 or < -1), these data were log transformed and z-
Table 2
Biomarker evaluation for cardiovascular death data in prediction models with and without betatrophin.
Outcome Model AUC Harrell's C Somers’D IDI
NRI
p-value
CV death default 0.771 0.757 0.515 0.070 0.003
default þ betatrophin 0.780 0.768 0.536 0.764 <0.001
CV death SCORE 0.717 0.625 0.250 0.068 0.002
SCORE þ Betatrophin 0.732 0.665 0.330 0.794 <0.001
Betatrophin's ability to improve risk stratification for cardiovascular death is analyzed by comparing a default cardiovascular risk
model (“default”) comprising continuous variables age, sex, BMI, LDL, HDL, triglycerides, and categorical variables hypertension
status, the current smoking status, the diabetes mellitus type 2 status, and the significant CAD status to a model additionally
comprising the betatrophin status as a categorical variable (“default þ Betatrophin”). Similarly, the ESC-proposed SCORE al-
gorithmmodel (“SCORE”) comprising continuous variables age, sex, total cholesterol, systolic blood pressure, and the categorical
variable current smoking status was compared to the SCORE model comprising all mentioned variables and in addition beta-
trophin status as a categorical variable (SCOREþBetatrophin”). Models were built as linear predictor scores after Cox regression.
Harrell’s C, Somers’ D and the area under the curve (AUC) for the receiver operator characteristic (ROC) are given. Integrated
discrimination improvement (IDI) and net reclassification improvement (NRI) indices for the addition of betatrophin to the basic
model are given with respective p-values at follow up end.
A. Leiherer et al. / Data in brief 28 (2020) 1049894transformed before analysis. In order to examine the value of uromodulin as a biomarker [2] several
cox regression models were fitted with the respective study endpoint as the dependent variable and c-
statistics were applied. The respective models were compared according to their linear predictor score
using calculation of area under the curve (AUC), Harrell's C and Somers' D, as well as integrated
discrimination improvement (IDI) and net reclassification improvement (NRI) indices. All missing
values were missing completely at random (MCAR), according to Little's MCAR test. All data were
analyzed according to complete case analysis. All statistical analyses as described in this data article
were performed with SPSS 26.0 for Windows (SPSS, Inc., Chicago, IL) and R statistical software v. 3.6.1
(http://www.r-project.org) including specific software packages (survIDINRI [3,4]).
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